National Pension Service Has $2.75 Million Stake in Neurocrine Biosciences, Inc. $NBIX

National Pension Service reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 48.0% during the second quarter, Holdings Channel.com reports. The firm owned 16,310 shares of the company’s stock after selling 15,042 shares during the quarter. National Pension Service’s holdings in Neurocrine Biosciences were worth $2,749,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. WINTON GROUP Ltd bought a new position in shares of Neurocrine Biosciences in the second quarter valued at $270,000. Engineers Gate Manager LP raised its holdings in shares of Neurocrine Biosciences by 64.0% in the 2nd quarter. Engineers Gate Manager LP now owns 18,361 shares of the company’s stock worth $3,094,000 after acquiring an additional 7,163 shares during the last quarter. RFG Advisory LLC acquired a new stake in shares of Neurocrine Biosciences in the 2nd quarter worth about $1,381,000. IFP Advisors Inc lifted its position in Neurocrine Biosciences by 7.7% in the 2nd quarter. IFP Advisors Inc now owns 3,008 shares of the company’s stock valued at $507,000 after acquiring an additional 216 shares in the last quarter. Finally, Baird Financial Group Inc. lifted its position in Neurocrine Biosciences by 3.3% in the 2nd quarter. Baird Financial Group Inc. now owns 39,868 shares of the company’s stock valued at $6,719,000 after acquiring an additional 1,279 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the company. Truist Financial boosted their price objective on Neurocrine Biosciences from $200.00 to $213.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Sanford C. Bernstein began coverage on Neurocrine Biosciences in a report on Friday, May 22nd. They issued an “outperform” rating and a $221.00 target price on the stock. Needham & Company LLC lifted their target price on Neurocrine Biosciences from $200.00 to $204.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Guggenheim upped their price target on Neurocrine Biosciences from $200.00 to $222.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $198.00 price target on shares of Neurocrine Biosciences in a research report on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $201.09.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Leslie Norwalk sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $182.01, for a total value of $227,512.50. Following the completion of the transaction, the director owned 1,588 shares in the company, valued at $289,031.88. This trade represents a 44.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Darin Lippoldt sold 10,000 shares of Neurocrine Biosciences stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $179.60, for a total value of $1,796,000.00. Following the transaction, the insider directly owned 54,729 shares of the company’s stock, valued at $9,829,328.40. The trade was a 15.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 40,188 shares of company stock valued at $7,118,633 over the last three months. Company insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Stock Performance

Shares of NBIX stock opened at $156.22 on Monday. The firm’s 50 day moving average is $164.46 and its 200 day moving average is $151.42. The stock has a market capitalization of $15.88 billion, a P/E ratio of 22.91, a PEG ratio of 0.73 and a beta of 0.38. Neurocrine Biosciences, Inc. has a 12 month low of $122.14 and a 12 month high of $186.12.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Friday, July 31st. The company reported $2.85 earnings per share for the quarter, beating analysts’ consensus estimates of $1.65 by $1.20. Neurocrine Biosciences had a net margin of 20.91% and a return on equity of 22.43%. The business had revenue of $959.00 million during the quarter, compared to analyst estimates of $891.16 million. During the same period in the previous year, the business earned $1.65 EPS. Neurocrine Biosciences’s revenue was up 39.5% compared to the same quarter last year. On average, equities analysts predict that Neurocrine Biosciences, Inc. will post 7.25 EPS for the current year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company develops therapies for conditions with significant unmet medical needs, using expertise in neuroscience and endocrine biology.

Its primary commercial product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.